In Part I of a three-part article, the authors discuss what constitutes an impurity and the potential sources of impurities in APIs and finished drug products. To ensure the quality of APIs and ...
While downgrading the impact of nitrosamine impurities on patients, FDA vows to step up investigations for other drug types. FDA lowered its estimate of the impact on patients of nitrosamine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results